Finance

Lists
RHHBY:OTCMKTS
Roche Holdings AG Basel ADR Common Stock
$54.70
+1.45%
(+0.78) 1D
$54.70
0.00% (0.00)
After hours
Closed: Jul 24, 4:00:00 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for RHHBY...
Open
$54.48
High
$54.84
Low
$54.06
Mkt. cap
352.50B
Avg. vol.
1.80M
Volume
3.51M
P/E ratio
22.28
52-wk high
$60.85
52-wk low
$37.51
EPS
$2.46
Beta
0.46
Shares outstanding
5.62B
No. of employees
113K
Open
$54.48
High
$54.84
Low
$54.06
Mkt. cap
352.50B
Avg. vol.
1.80M
Volume
3.51M
P/E ratio
22.28
52-wk high
$60.85
52-wk low
$37.51
EPS
$2.46
Beta
0.46
Shares outstanding
5.62B
No. of employees
113K
News stories
From sources across the web
Profile
F. Hoffmann-La Roche AG, commonly known as Roche, is a Swiss multinational holding healthcare company that operates worldwide under two divisions: Pharmaceuticals and Diagnostics. Its holding company, Roche Holding AG, has shares listed on the SIX Swiss Exchange. The company headquarters are located in Basel. Roche is the fifth-largest pharmaceutical company in the world by revenue and the leading provider of cancer treatments globally. In 2023, the company’s seat in Forbes Global 2000 was 76. The company owns the American biotechnology company Genentech, which is a wholly owned independent subsidiary, and the Japanese biotechnology company Chugai Pharmaceuticals, as well as the United States–based companies Ventana and Foundation Medicine. Roche's revenues during fiscal year 2020, were 58.32 billion Swiss francs. Descendants of the founding Hoffmann and Oeri families own slightly over half of the bearer shares with voting rights, with Swiss pharma firm Novartis owning a further third of its shares until 2021. F. Hoffmann-La Roche is a full member of the European Federation of Pharmaceutical Industries and Associations. Wikipedia
About Roche Holdings AG Basel ADR Common Stock
CEOThomas Schinecker
Employees113K
FoundedOct 1, 1896
HeadquartersBasel, Basel City, Switzerland
SectorPharmaceutical industry
Websiteroche.com
Previous reportsAll values in CHF
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in CHF
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
15.75B
15.75B
15.73B
15.73B
Cost of goods sold
4.21B
4.21B
3.99B
3.99B
Cost of revenue
4.21B
4.21B
3.99B
3.99B
Research and development expenses
3.15B
3.15B
3.62B
3.62B
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
3.59B
3.59B
3.40B
3.40B
Operating expense
6.82B
6.82B
6.90B
6.90B
Total operating expenses
11.03B
11.03B
10.89B
10.89B
Operating income
4.72B
4.72B
4.84B
4.84B
Other non operating income
-1.50M
-1.50M
-28.00M
-28.00M
EBT including unusual items
3.69B
3.69B
4.49B
4.49B
EBT excluding unusual items
4.37B
4.37B
4.49B
4.49B
Income tax expense
709.00M
709.00M
824.00M
824.00M
Effective tax rate
19.20%
19.20%
18.37%
18.37%
Other operating expenses
77.50M
77.50M
-115.00M
-115.00M
Net income
2.74B
2.74B
3.44B
3.44B
Net profit margin
17.36%
17.36%
21.85%
21.85%
Earnings per share
-
-
-
-
Interest and investment income
45.00M
45.00M
-
-
Interest expense
-289.50M
-289.50M
-321.00M
-321.00M
Net interest expenses
-244.50M
-244.50M
-321.00M
-321.00M
Depreciation and amortization charges
-
-
-
-
EBITDA
5.50B
5.50B
5.62B
5.62B
Gain or loss from assets sale
-21.50M
-21.50M
-2.50M
-2.50M
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

What's on your mind?
What's going on with the markets today?
Explore what’s possible
Create a portfolio
Create a task
Deep Search
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer